CLINICAL SCIENCE

Guidance for Authors

CONTENTS

1. POLICY OF THE JOURNAL

1.1. Scope

Clinical Science publishes papers in the field of clinical investigation, provided they are of a suitable standard and contribute to the advancement of knowledge in this field. The term ‘clinical investigation’ is used in its broad sense to include studies in animals and the whole range of biochemical, physiological, immunological and other approaches that may have relevance to disease in man. Studies which are confined to normal subjects, or animals, or are purely methodological in nature may be acceptable. The material presented should permit conclusions to be drawn and should not be only of a preliminary nature. The journal publishes four types of manuscript, namely invited Editorial Reviews, Full Papers, Short Communications and Correspondence. In addition, Clinical Science publishes abstracts of the proceedings of the Medical Research Society and also that Society's Annual Guest Lecture.

1.2. The Editorial Board

The Board comprises Editors for the Medical Research Society and the Biochemical Society and a Chairman and Deputy Chairman who are drawn alternately from the two Societies. Members of the Board retire after a maximum of 5 years; the Chairman serves in his capacity for 2 years. The membership of the Board is designed to cover as wide a range of interests as possible.

The main function of the Board is to decide on the acceptability of submitted papers, but it also deals with general matters of editorial policy. Financial policy is dealt with separately by the Committee of Management.

1.3. The editorial process

A submitted paper is first read by the Chairman of the Editorial Board who then sends it to an Editor. The latter considers the paper in detail and sends it to one or more referees (who remain anonymous) from outside the membership of the Board. The Editor returns it with his recommendation to the Chairman who then writes formally to...
the authors. The ultimate responsibility of acceptance for publication lies with the Chairman. If the Chairman is for any reason unavailable, the Deputy Chairman assumes this function.

1.4. Ethics of investigations on human subjects

Authors must state in the text of their paper the manner in which they have complied, where necessary, with the recommendations on human investigations published in the Medical Research Council report of 1962/63 [British Medical Journal (1964) ii, 178–180]. Consent must be obtained from each patient or subject after full explanation of the purpose, nature and risks of all procedures used and the fact that such consent has been given should be recorded in the paper. Papers should also state that the Ethical Committee of the Institution in which the work was performed has given approval to the protocol. The Editorial Board will not accept papers the ethical aspects of which are, in the Board’s opinion, open to doubt.

1.5. Originality of papers

Submission of a paper to the Editorial Board is taken to imply that it reports unpublished work, that it is not under consideration for publication elsewhere and that, if accepted for publication by Clinical Science, it will not be published elsewhere in the same form, either in English or in any other language, without the consent of the Editorial Board. This does not usually apply to previous publication of oral communications in brief abstract form. In such cases authors should enclose copies of the abstracts. When a paper has been accepted for publication the author, or in the case of multiple authorship the author with whom correspondence has taken place, will be asked to sign a statement vesting the copyright in the Editorial Board. Requests for consent for reproduction of material published in Clinical Science should be addressed to the Editorial Manager.

2. SUBMISSION OF MANUSCRIPTS:
GENERAL INFORMATION AND FORMAT

2.1. General

Papers submitted for publication should be sent to the Editorial Manager, Clinical Science, 7 Warwick Court, London WC1R 5DP.

The submission should contain four copies (of which three may be photocopies) of the typescript, Tables, Figures etc. The authors should retain one copy of the paper. The Editorial Board does not accept responsibility for damage or loss of papers submitted, although great care is taken to ensure safety and confidentiality of the typescript during the editorial process. In the case of multiple authorship, the covering letter should indicate that the approval of all co-authors has been obtained.

Papers should be presented so that they are intelligible to the non-specialist reader of the journal. This is particularly important in highly specialized fields and a very brief résumé of the current state of knowledge is usually helpful. Certain types of material, e.g. mathematical formulations requiring more than trivial derivations, should be given in a separate Appendix.

Where the reader is referred to previous works by the same author(s) for important details relevant to the present work, it often speeds up assessment if reprints are enclosed with the typescript. This is of particular importance in relation to methodology.

The dates of receipt and acceptance of the paper will be published. If the paper has to be returned to the authors for revision and is not resubmitted within 1 month, the date of receipt will be revised accordingly. For Short Communications the published date will always be that of receipt of the final version. It is emphasized that badly presented or unduly long papers will be returned for revision and delays in publication will be inevitable. Similar delays will be incurred if the typescript is not prepared strictly in accordance with the instructions detailed below.

2.2. Full papers

The authors should refer to a current issue of Clinical Science to make themselves familiar with the general layout. Concise presentation is very important for rising costs are a severe constraint on space. The length of manuscript and the number of Figures and Tables must be kept to a minimum. Extensive Tables of data can be deposited with the Royal Society of Medicine (see 2.5). Guidance for Authors is usually published in the January issue of the journal, and revised periodically.

Typescripts should be, in general, arranged as follows:

(a) Title page. Title: this should be as informative as possible, since titles of papers are being increasingly used in indexing and coding for information storage and retrieval. The title should indicate the species in which the observations reported have been made. The numbering of parts in a series of papers is not permitted.
Guidance for Authors

List of authors' names (degrees and appointments are not required).

Laboratory or Institute of origin.

Key words: for indexing the subject of the paper; they should, if possible, be selected from the current issues of 'Medical Subject Headings' (MeSH), produced by the Index Medicus.

Short title: for use as a running heading in the printed text; it should not exceed forty-five characters and spaces.

Author for correspondence: the name and address of the author to whom queries and requests for reprints should be sent.

(b) **Summary.** This should be a brief statement arranged in numbered paragraphs of what was done, what was found and what was concluded and should rarely exceed 250 words. Contributors from non-English speaking countries are invited to include a translation of the summary in their own language. Abbreviations should be avoided as far as possible and must be defined. Statistical and methodological details including exact doses should also be avoided unless they are essential to the understanding of the summary.

(c) **Introduction.** This should contain a clear statement of the reason for doing the work, but should not include either the findings or the conclusions.

(d) **Methods.** The aim should be to give sufficient information in the text or by reference to permit the work to be repeated without the need to communicate with the author.

(e) **Results.** This section should not include material appropriate to the Discussion section.

(f) **Discussion.** This should not contain results and should be pertinent to the data presented.

(g) **Acknowledgments.** These should be as brief as possible.

(h) **References.** See p. v for the correct format.

(i) **Figures and Tables.** See p. iv.

2.3. **Short Communications**

The Short Communication should describe completed work, and should not be merely a preliminary communication. The format of Short Communications should be similar to that of Full Papers, but should not exceed 1200 words of text. **One Figure or Table** is allowed, but if neither is included the text may be expanded to 1400 words. The passage of Short Communications through the editorial process can frequently be expedited and contributors are encouraged to take advantage of these facilities when rapid publication is of importance and the material can be presented concisely.

The paper should appear in print within 3 months of acceptance. When submitting Short Communications, authors should make it quite clear that the work is intended to be treated as a Short Communication.

2.4. **Correspondence**

Letters containing critical assessments of material published in *Clinical Science*, including Editorial Reviews, will be considered for the Correspondence section of the journal. Such letters should be sent to the Editorial Manager, *Clinical Science*, within 6 months of the appearance of the article concerned. They will be sent to the authors for comment and both the letter and any reply by the author will be published together. Further correspondence arising therefrom will also be considered for publication. Consideration will also be given to publication of letters on ethical matters.

2.5. **Arrangements for large amounts of information**

It is impracticable to publish very large sets of individual values or very large numbers of diagrams, and under these circumstances a summary of the information only should be included in the paper. The information from which the summary was derived should be submitted with the typescript and, if the latter is accepted, the Editors may ask for a copy of the full information and diagrams to be deposited with the Librarian, the Royal Society of Medicine, 1 Wimpole Street, London W1M 8AE, who will issue copies on request. Experience has shown that such requests are frequently received.

2.6. **Proof corrections**

These are expensive and corrections of other than printers' errors may have to be charged to the author.

2.7. **Offprints**

Fifty offprints are supplied free and additional copies may be obtained at terms, based upon the cost of production, that will be given with the proofs. All offprints should be ordered when the proofs are returned.

2.8. **Availability on MEDLINE**

Summaries of papers in *Clinical Science* are available on-line on teleprinters participating in the MEDLINE system run by the National Library of Medicine, National Institutes of Health, Bethesda, Maryland, U.S.A.
3. MISCELLANEOUS NOTES

3.1. Abbreviations
Abbreviations should be avoided; if used they must be defined at the first mention; new abbreviations should be coined only for unwieldy names which occur frequently. Abbreviations should not appear in the title nor, if possible, in the Summary. A list of accepted abbreviations is on p. vi. Numbers, not initials, should be used for patients and subjects.

3.2. Anatomical nomenclature
This should follow the recommendations of the International Anatomical Nomenclature Committee (1966) Nomina Anatomica, 3rd edn, Excerpta Medica Foundation, Amsterdam.

3.3. Animals, plants and micro-organisms
The full binomial specific names should be given at first mention for all experimental animals other than common laboratory animals. The strain and, if possible, the source of laboratory animals should be stated. Thereafter in the text, single letter abbreviations may be given for the genus; if two genera with the same initial letter are studied, abbreviations such as \textit{Staph.} and \textit{Strep.} should be used.

3.4. Buffers and salts
The acidic and basic components should be given, together with the pH. Alternatively, a reference to the composition of the buffer should be given. Further details are provided in the \textit{Biochemical Journal} (1978) 169, 9.

When describing solutions containing organic anions and their parent acids, the salt designator (e.g. lactate, urate, oxalate) should be used in preference to the name of the acid (lactic, uric, oxalic) unless it is certain that virtually all of the acid is in the undissociated form.

The composition of incubation media should be described, or a reference to the composition should be given.

3.5. Computer modelling
Papers concerned primarily with computer modelling techniques are acceptable provided that use of such techniques leads to a clear choice between two or more alternative hypotheses, or to the formulation of a new hypothesis amenable to experimental challenge or verification, or provides some new insight into the behaviour of a particular physiological system. Extensive technical details of hardware and software should not be given.

3.6. Doses
Doses of drugs should be expressed in mass terms, e.g. milligrams (mg) or grams (g), and also (in parentheses) in molar terms, e.g. mmol, mol, where this appears to be relevant. Molecular weights of many drugs may be found in \textit{The Merck Index}, 8th edn, Merck and Co. Inc., N.J., U.S.A.

3.7. Enzymes
Nomenclature should follow that given in \textit{Enzyme Nomenclature} (1978), Academic Press, London and New York, and Enzyme Commission (EC) number should be quoted at the first mention. Where an enzyme has a commonly used informal name, this may be employed after the first formal identification. A unit of enzyme activity should preferably be expressed as that amount of material which will catalyse transformation of 1 μmol of the substrate/min under defined conditions, including temperature and pH. Alternatively, or when the natural substrate has not been fully defined, activity should be expressed in terms of units of activity relative to that of a recognized reference preparation, assayed under identical conditions. Activities of enzymes should normally be expressed as units/ml or units/mg of protein.

3.8. Evaluation of measurement procedures
When a new measuring procedure has been used, or when an established procedure has been applied in a novel fashion, an estimate of the precision of the procedure should be given. This should, as far as possible, indicate what sources of variation have been included in this estimate, e.g. variation of immediate replication, variation within different times of day, or from day to day etc.

If the precision of measurement varies in proportion to the magnitude of the values obtained, it can best be expressed as the coefficient of variation; otherwise it should be expressed by an estimate of the (constant) standard error of a single observation, or by estimates at several points within the range of observed values.

When recovery experiments are described the approximate ratio of the amount added to the amount already present and the stage of the procedure at which the addition was made should be stated.

3.9. Figures and Tables
These are expensive to print and their number should be kept to a minimum. Their appropriate position in the paper should be indicated in the margin of the text. References to Figures and
Tables should be in Arabic numerals, e.g. Fig. 3, and they should be numbered in order of appearance. In general, the same data should not be presented in both a Figure and a Table.

Figures, with captions attached, should be supplied as original drawings or matt photographs together with photocopies. All Figures should have their number and the authors’ names written in pencil on the back; the top of the Figure should be indicated with a pencilled arrow. Acceptable symbols for experimental points are *, △, □, ◊, ◆. The symbols × or + must be avoided. The same symbols must not be used for two curves where the points might be confused. For scatter diagrams, solid symbols are preferred. When a particular variable appears in more than one Figure, the same symbol should be used for it throughout, if possible.

Curves should not be drawn beyond the experimental points, nor should axes extend appreciably beyond the data. Only essential information that cannot readily be included in the legend should be written within the Figure.

Figures for half-tone reproduction should be submitted as glossy prints. They are particularly expensive to print and their use should be avoided as far as possible.

Tables should be typed separately from the text. They should have an underlined title followed by any legend.

Captions for the Figures, and titles and legends for the Tables, should make them readily understandable without reference to the text. Adequate statistical information, including that on regression lines, should be included in Figure captions where appropriate.

3.10. Footnotes

These should be avoided as far as possible but where they are used in Tables they should be identified by the symbols * † ‡ § ¶ in that order.

3.11. Isotope measurements

The information given should include (a) conditions of radioactivity counting, e.g. infinitely thick, infinitely thin; (b) the nature of the phosphor used in liquid-scintillation counting; (c) details of corrections made to the observed count rate, e.g. for ‘quenching’ or ‘cross-over’; (d) standard deviation of the results or a statement of the minimum total counts above background collected and the background value.

In general the specific radioactivity of the starting materials should be given, preferably in terms of radioactivity per unit weight or, for stable isotopes, as atoms % excess.

Pending the general introduction of SI units radioactivity should continue to be expressed in terms of the curie (Ci) followed by the corresponding figure in terms of the becquerel (Bq: disintegrations/s), in parentheses, and suitably rounded.

3.12. Radionuclide applications in man

If new or modified radionuclide applications in man are described, an estimate of the maximal possible radiation dose to the body and critical organs should be given.

For the time being this can continue to be expressed in rems, but with the corresponding figure in sieverts (Sv) given in parentheses after it.

3.13. Methods

In describing certain techniques, namely centrifugation (when the conditions are critical), chromatography and electrophoresis, authors should follow the recommendations published by the Biochemical Society (currently, Biochemical Journal (1981) 193, 1−21).


This should follow the International Classification of Disease (8th revision, World Health Organization, Geneva, 1969) as far as possible.

3.15. Powers in Tables and Figures

Care is needed where powers are used in Table headings and in Figures to avoid numbers with an inconvenient number of digits. For example: (i) an entry ‘2’ under the heading $10^3k$ means that the value of $k$ is 0.002; an entry ‘2’ under the heading $10^{-3}k$ means that the value of $k$ is 2000. (ii) A concentration 0.00015 mol/l may be expressed as 0.15 under the heading ‘concn. (mmol/l)’ or as 150 under the heading ‘concn. (umol/l)’ or as 15 under the heading ‘$10^3$ × concn. (mol/l)’, but not as 15 under the heading ‘concn. (mol/l × $10^{-3}$)’.

3.16. References

The numerical citation system is now used: references in the text are numbered consecutively in the order in which they are first mentioned, the numerals being given in brackets, e.g. [22]. References cited in Figure legends or Tables only should be numbered in a sequence determined by the position of the first mention in the text of the Figure or Table. References should be listed in
numerical order and the names of all authors of a paper should be given, with the full title of the paper and the source details in full including the first and last page numbers, e.g.


When the quotation is from a book, the following format should be used, giving the relevant page or chapter number:


References to 'personal communications' and 'unpublished work' should appear in the text only and not in the list of references. The name and initials of the source of information should be given. When the reference is to material that has been accepted for publication but has not yet been published, this should be indicated in the list of references by 'In press' together with the name of the relevant journal and, if possible, the expected date of publication. If such a citation is of major relevance to the manuscript submitted for publication authors are advised that the editorial process might be expedited by the inclusion of a copy of such work. In the case of quotations from personal communications the authors should state in the covering letter that permission for quotation has been obtained.

3.17. Solutions

Concentration of solutions should be described where possible in molar terms (mol/l and subunits thereof), stating the molecular particle weight if necessary. Values should not be expressed in terms of normality or equivalents. Mass concentration should be expressed as g/l or subunits thereof, for example mg/l or µg/l. For solutions of salts, molar concentration is always preferred to avoid ambiguity as to whether anhydrous or hydrated compounds are used. Concentrations of aqueous solutions should be given as mol/l or mol/kg (g/l or g/kg if not expressed in molar terms) rather than % (w/v) or % (w/w). It should always be made clear whether concentrations of components in a reaction mixture are final concentrations or the concentrations in solutions added.

3.18. Spectrophotometric data

The term ‘absorbance’ [log (I/I₀)] should be used rather than ‘optical density’ or ‘extinction’. The solvent, if other than water, should be specified. Symbols used are: A, absorbance; a, specific absorption coefficient (litre g⁻¹ cm⁻¹) (alternatively use A[γ]cm⁻¹); ε, molar absorption coefficient (the absorbance of a molar solution in a 1 cm light-path) (litre mol⁻¹ cm⁻¹, not cm² mol⁻¹).

3.19. Spelling

Clinical Science uses as standards for spelling the Concise or Shorter Oxford Dictionary of Current English (Clarendon Press, Oxford) and Butterworth’s Medical Dictionary (Butterworths, London).

3.20. Statistics

Papers are frequently returned for revision (and their publication consequently delayed) because the authors use inappropriate statistical methods. Two common errors are the use of means, standard deviations and standard errors in the description and interpretation of grossly non-normally distributed data and the application of t-tests for the significance of difference between means in similar circumstances, or when the variances of the two groups are non-homogeneous. In some circumstances it may be more appropriate to provide a ‘scattergram’ than a statistical summary.

A reference should be given for all methods used to assess the probability of a result being due to chance. The format for expressing mean values and standard deviations or standard errors of the mean is, for example: mean cardiac output 10·4 l/min (SD 1·2; n = 11). Degrees of freedom should be indicated where appropriate. Levels of significance are expressed in the form P < 0·01.

3.21. Trade names

The name and address of the supplier of special apparatus and of biochemicals should be given. In the case of drugs, approved names should always be given with trade names and manufacturers in parentheses.

4. UNITS: THE SI SYSTEM

The recommended Système International (SI) units [see Quantities, Units and Symbols, 2nd edn (1975) The Royal Society, London] are used by Clinical Science. All papers submitted should use these units except for blood pressure values, which should be expressed in mmHg, or gas tensions, where values at the author's discretion may be given as mmHg (with kPa in parentheses) or as kPa (with mmHg in parentheses) in the text and either as mmHg or as kPa in Figures, which (if practicable) should have scales in both units. Airways pressure should be expressed in kPa. Where molecular weight is known, the amount of a chemical or drug should be expressed in mol or in
an appropriate subunit, e.g. mmol. Energy should be expressed in joules (J).

The basic SI units and their symbols are as follows:

<table>
<thead>
<tr>
<th>Physical quantity</th>
<th>Name</th>
<th>Symbol</th>
</tr>
</thead>
<tbody>
<tr>
<td>length</td>
<td>metre</td>
<td>m</td>
</tr>
<tr>
<td>mass</td>
<td>kilogram</td>
<td>kg</td>
</tr>
<tr>
<td>time</td>
<td>second</td>
<td>s</td>
</tr>
<tr>
<td>electric current</td>
<td>ampere</td>
<td>A</td>
</tr>
<tr>
<td>thermodynamic temperature</td>
<td>kelvin</td>
<td>K</td>
</tr>
<tr>
<td>luminous intensity</td>
<td>candela</td>
<td>cd</td>
</tr>
<tr>
<td>amounts of substance</td>
<td>mole</td>
<td>mol</td>
</tr>
</tbody>
</table>

The following are examples of derived SI units:

<table>
<thead>
<tr>
<th>Physical quantity</th>
<th>Name</th>
<th>Symbol</th>
</tr>
</thead>
<tbody>
<tr>
<td>energy</td>
<td>joule</td>
<td>J</td>
</tr>
<tr>
<td>force</td>
<td>newton</td>
<td>N</td>
</tr>
<tr>
<td>power</td>
<td>watt</td>
<td>W</td>
</tr>
<tr>
<td>pressure</td>
<td>pascal</td>
<td>Pa</td>
</tr>
<tr>
<td>electric charge</td>
<td>coulomb</td>
<td>C</td>
</tr>
<tr>
<td>electric potential</td>
<td>volt</td>
<td>V</td>
</tr>
<tr>
<td>electric resistance</td>
<td>ohm</td>
<td>Ω</td>
</tr>
<tr>
<td>electric conductance</td>
<td>siemens</td>
<td>S</td>
</tr>
<tr>
<td>electric capacitance</td>
<td>farad</td>
<td>F</td>
</tr>
<tr>
<td>frequency</td>
<td>hertz</td>
<td>Hz</td>
</tr>
<tr>
<td>volume</td>
<td>litre</td>
<td>l</td>
</tr>
</tbody>
</table>

The word 'litre' has been accepted as a special name for cubic decimetre (1 litre = 1 dm³).

Both the basic and derived SI units, including the symbols of derived units that have special names, may be preceded by prefixes to indicate multiples and submultiples. The prefixes should be as follows:

<table>
<thead>
<tr>
<th>Prefix</th>
<th>Symbol</th>
<th>Multiple</th>
<th>Prefix</th>
<th>Symbol</th>
</tr>
</thead>
<tbody>
<tr>
<td>10⁶</td>
<td>mega</td>
<td>M</td>
<td>10⁻³</td>
<td>milli</td>
</tr>
<tr>
<td>10³</td>
<td>kilo</td>
<td>k</td>
<td>10⁻⁶</td>
<td>micro</td>
</tr>
<tr>
<td>10²</td>
<td>hecto</td>
<td>h</td>
<td>10⁻⁹</td>
<td>nano</td>
</tr>
<tr>
<td>10¹</td>
<td>deka</td>
<td>da</td>
<td>10⁻¹²</td>
<td>pico</td>
</tr>
<tr>
<td>10⁻¹</td>
<td>deci</td>
<td>d</td>
<td>10⁻¹⁵</td>
<td>femto</td>
</tr>
<tr>
<td>10⁻²</td>
<td>centi</td>
<td>c</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* To be avoided where possible (except for cm).

Compound prefixes should not be used, e.g. 10⁻⁹ m should be represented by 1 nm, not 1 μm.

Notes:

(i) Full stops are not used after symbols.
(ii) Minutes (min), hours (h), days and years will continue to be used in addition to the SI unit of time (the second (s)).
(iii) The solidus may be used in a unit as long as it does not have to be employed more than once, e.g. mmol/l is acceptable, but ml/min/kg is not, and should be replaced by ml min⁻¹ kg⁻¹.

5. ABBREVIATIONS, CONVENTIONS, DEFINITIONS, SYMBOLS AND SPECIAL COMMENTS

As well as standard symbols and abbreviations that have been accepted by international bodies, and which can be used without definition, this list shows selected abbreviations in the form of groups of capital letters (e.g. ALA, ECF, MCHC) which when used must be defined in the text as indicated on p. iv. The standard abbreviations for amino acids are only for use in Figures and Tables or for peptide sequences.

<table>
<thead>
<tr>
<th>Name</th>
<th>Symbol</th>
</tr>
</thead>
<tbody>
<tr>
<td>absorbance</td>
<td>A</td>
</tr>
<tr>
<td>acceleration due to gravity</td>
<td>g</td>
</tr>
<tr>
<td>adenosine 3':5'-cyclic mono-phosphate</td>
<td>cyclic AMP</td>
</tr>
<tr>
<td>adenosine 5'-phosphate</td>
<td>AMP</td>
</tr>
<tr>
<td>adenosine 5'-pyrophosphate</td>
<td>ADP</td>
</tr>
<tr>
<td>adenosine 5'-triphosphate</td>
<td>ATP</td>
</tr>
<tr>
<td>adrenocorticotropic hormone</td>
<td>ACTH</td>
</tr>
<tr>
<td>adrenoceptor (see also blocking agents)</td>
<td>Ala</td>
</tr>
<tr>
<td>alanine</td>
<td>Ala</td>
</tr>
<tr>
<td>alternating current</td>
<td>a.c.</td>
</tr>
<tr>
<td>alveolar minute ventilation</td>
<td>V A/V</td>
</tr>
<tr>
<td>alveolar to arterial oxygen</td>
<td>tension difference</td>
</tr>
<tr>
<td>ampare</td>
<td>A</td>
</tr>
<tr>
<td>aminolaevulinic acid</td>
<td>angiotensin</td>
</tr>
<tr>
<td>Angstrom (Å)</td>
<td>not used; express in nm (1 Ångstrom = 10⁻¹ nm)</td>
</tr>
<tr>
<td>antidiuretic hormone</td>
<td>ADH (when referring to the physiological secretion)</td>
</tr>
<tr>
<td>arginine</td>
<td>Arg</td>
</tr>
<tr>
<td>arteriovenous</td>
<td>a—v: permitted in Figures and Tables</td>
</tr>
<tr>
<td>asparagine</td>
<td>Asn</td>
</tr>
<tr>
<td>aspartic acid</td>
<td>Asp</td>
</tr>
<tr>
<td>atmosphere (unit of pressure)</td>
<td>not used; express in kPa (1 atmosphere = 101.325 kPa)</td>
</tr>
<tr>
<td>atomic weight</td>
<td>at. wt.</td>
</tr>
<tr>
<td>becquerel</td>
<td>Bq (1 d.p.s.)</td>
</tr>
<tr>
<td>blocking agents</td>
<td>e.g. β-adrenoceptor antagonists preferred express in mmHg not used; recalculate as urea, express in mmol/l</td>
</tr>
<tr>
<td>blood pressure</td>
<td>BY</td>
</tr>
<tr>
<td>blood urea nitrogen</td>
<td>BTPS</td>
</tr>
<tr>
<td>blood volume</td>
<td></td>
</tr>
<tr>
<td>body temperature and pressure, saturated</td>
<td></td>
</tr>
</tbody>
</table>
Guidance for Authors

- British Pharmacopoeia
- calculated
- ‘Calorie’ (= 1000 cal)
- calculated
- ‘Calorie’ (= 1000 cal)
- carbon dioxide output (in respiratory physiology)
- cardiac frequency
- cardiac output
- centimetre
- clearance of x
- coenzyme A and its acyl derivatives
- compare
- complement fractions
- compliance (respiratory physiology)
- concentrated
- concentration
- conductance (respiratory physiology)
- correlation coefficient
- counts/min, counts/s
- cubic centimetres
- curie
- cycle/s
- cysteine
- dates
- dead-space minute ventilation
- dead-space volume
- degrees, Celsius or centigrade
- deoxy (prefix)
- deoxycorticosterone
- deoxycorticosterone acetate
- deoxyribonucleic acid
- dialysate
- diethylaminoethylcellulose
- differential of x with respect to time
- 1,25-dihydroxycholecalciferol
dilute
- 2,3-diphosphoglycerate
- direct current
- disintegrations/min
- disintegrations/s
- dissociation constant
- acidic
- basic
- apparent
- minus log of
- doses
- dyne
- elastance
- electrocardiogram
- electroencephalogram
- write in full and give
edition
- calc. (in Tables only)
- not used; recalculate as kilojoules (1 'Calorie' = 4.184 kJ)
- $V_{co}$; express in ml
- STP/min
- $f_c$; in beats/min
- express in l/min
- cm
- $C_o$
- CoA and acyl-CoA
- cf.
- C1–C9
- $C_o$; express in 1 kPa$^{-1}$
- conc.
- concn.; may be denoted
- [ ]; e.g. plasma
- $[\text{HCO}_3^-]$ $G$; express in 1 s$^{-1}$ kPa$^{-1}$
- $r$: may be used without definition
- c.p.m., c.p.s.
- use ml
- Ci (1 Ci = $3.7 \times 10^{10}$ d.p.s.)
- Hz
- Cys
- e.g. 11 August 1970
- $V_o$
- $\phi_o$
- $\phi_c$
- not deoxy
- DOC
- DNA
- diffuse preferred;
- 'dialysate' should be clearly defined
- DEAE-cellulose
- $x (= \frac{dx}{dt})$
- 1,25-\(\text{(OH)}_2\)D$_3$
dilute
- 2,3-DPG
dil.
- d.c.
d.p.m.
d.p.s.
- $K_a$
- $K_b$
e.g. $K_a$
pK
- avoid Latin designa-
tions such as b.d. and
- t.i.d.
dyn; used for vascular
- resistance
- $E$; express in Pa m$^{-3}$
- ECG
- EEG
- electromotive force
- electron spin resonance
- electronvolt
- equation
- equivalents (amount of a
- chemical)
- erythrocyte count
- erythrocyte sedimentation
- rate
- ethanol, ethanolic
- ethylenediaminetetra-acetate
- exchangeable
- Experiment (with reference
- numeral)
- expired minute ventilation
- extinction
- extracellular fluid
- extracellular fluid volume
- filtration (renal)
- Figure (with reference
- numeral)
- filtered load of x (renal)
- follicle-stimulating hormone
- forced expiratory volume in

- fractional concentration in
- dry gas
- fractional disappearance rate
- frequency of inspiration
- functional residual capacity
- gas–liquid chromatography
- gas transfer factor
- glomerular filtration rate
- glutamic acid
- glutamine
- glutathione
- glycine
- gram(me)
- gravitational field, unit of
- (9.81 m s$^{-2}$)
- growth hormone
- guanylyl cyclase
- haemoglobin
- half-life
- hertz (s$^{-1}$)
histidine
- hour
- human chorionic gon-
- adotropin
- human placental lactogen
- hydrocortisone
- hydrogen ion activity
- minus log of
- 25-hydroxycholecalciferol
- hydroxyproline
- immunoglobulins
- e.m.f.
e.s.r.
eV (for radiation
- energies)
eqn.
- not used; recalculate in
- molar terms
- express as 10$^{12}$ cells/l
- ESR
- EDTA
- Na+, K+, etc., for total
- exchangeable sodium,
- potassium etc.
- Expt.; plural, Expts.
- $\dot{V}_\text{E}$
- use absorbance
- ECF
- ECFV
- $E_r$
- Fig.; plural, Figs.
- $F_r$
- FSH
- FEV$_{1.0}$
- $F$
- $k$ (as in $A = Ae^{-kt}$)
- $f_c$; in breaths/min
- FRC
- g.l.c.
- $t$; in mmol min$^{-1}$ kPa$^{-1}$
- GFR
- Glu
- GSH (reduced); GSSG
- (oxidized)
- Gly
- $g$
- GD
- GH; if human, HGH
- Gy (100 rads)
- not allowed; use packed
cell volume (PCV)
- Hb; express in g/dl
- $i$
- Hz
- His
- h
- HCG
- HPL
- use cortisol
- aH; express in nmol/l
- pH
- 25-(OH)D$_3$
- Hyp
- IgA, IgD, IgE, IgG, IgM
injection routes: use abbreviations only in Figures

- intra-arterial: i.a.
- intramuscular: i.m.
- intraperitoneal: i.p.
- intravenous: i.v.
- subcutaneous: s.c.

in authors' discretion, for gas tensions: see p. vi (1 mmHg = 0.133 kPa)

- millimolar (concentration) mmol/l; not mM
- mmol
- mol
- mol/kg
- mol/l; not M

ε (the absorbance of a molar solution in a 1 cm light-path)

isotopically labelled compounds

- [U-14C]glucose,
- [1-14C]-sodium
- [1-14C]-acetate: use 131I-labelled albumin, not [131I]albumin

for simple molecules: 14CO2, 3H2O

molar absorption coefficient

normal temperature and pressure

use standard temperature and pressure (STP)

kilojoule

kilogram(me)

kilopond

lactate dehydrogenase

leucine

leucocyte count

lipoproteins (serum)

high density

low density

very low density

litre

logarithm (base 10)

logarithm (base e)

luteinizing hormone

lysine

maximum

mean corpuscular haemoglobin

mean corpuscular haemoglobin concentration

mean corpuscular haemoglobin volume

median lethal dose

metabolism

methanol, methanolic

methionine

metre

Michaelis constant

micromole

micron (10^-6 m)

milliequivalent

millilitre

millimetre of mercury

mole

molecular weight

nicotinamide-adenine dinucleotide

nicotinamide-adenine dinucleotide phosphate

normal

nuclear magnetic resonance

number (in enumerations) no. (in Tables only)

obs. (in Tables only)

Ω

Orn

ortho-

orthophosphate (inorganic)

osmolality

oxygen uptake per minute

packed cell volume

page, pages

para-

para-aminohippurate

partial pressure

e.g. alveolar, of O2

arterial, of CO2

capillary, of O2

mixed venous, of CO2

pascal

per

per cent

petroleum ether

phenylalanine

plasma renin activity

plasma volume

poise

PCV

p., pp.

p-

PAH

P; express in either kPa or mmHg (see p. vi)
Guidance for Authors

potential difference p.d.

power output

precipitate

pressure

probability of an event being due to chance alone

proline

protein-bound iodine (plasma)

pulmonary capillary blood flow

pyrophosphate (inorganic)

rad (radiation dose; 10^-5 J absorbed/g of material)

red blood cell

red cell mass

relative band speed (partition chromatography)

rem

renin

residual volume

resistance (rheological)

respiratory exchange ratio (pulmonary)

respiratory quotient (metabolic)

revolutions

rev./min

ribonucleic acid RNA

röntgen saline

saturation

second (time)

serine

sievevert

solvent systems

species

specific activity

specific conductance of airways

standard deviation

standard error of the mean

standard temperature and pressure

steroid nomenclature

sulphhydryl

sum

Svedberg unit

temperature (absolute)

(temperature, thermodynamic)

thin-layer chromatography

threonine

thyrotrophic hormone

thyrotrophin-releasing hormone

tidal volume

time (symbol)

time of day

torr

total lung capacity

tryptophan

tubular maximal reabsorptive capacity for x

tyrosine

ultraviolet

urinary concentration of x

valence

variance ratio

vascular resistance

ventilatory exchange rate

volume of blood

resistance (rheological)

volume of blood (in cardio-
respiratory physiology)

watt

wavelength

weight

white blood cell

sGaw; express in s^-1 kPa^-1

may be used

without definition

see Biochemical Journal (1969) 113, 5–28;
(1972) 127, 613–617

use thiol or SH

(1 torr = 0.133 kPa)

TLC

Trp

T_m,x

Tyr

u.v.

U_x

e.g., Fe^{2+}, not Fe^{3+}

Val

F

express in kPa l^-1 s (with value in dyn s cm^-5

in parentheses);

primary values of differen-
tial vascular pressure (mmHg) and

flow (l/min) should always also be given

in Tables or text as appropriate

v; express as m s^-1

\bar{Q}_v

used only for buffer mix-
tures; otherwise use

5,5'-diethylbarbituric acid

η

ν

VC

V

Q; use \dot{Q} for blood flow

rate

W

λ

wt.

use leucocyte; express
counts as 10^6 cells/l
Volume 60

AUTHOR INDEX

ALBERTI, K.G.M.M. 579–585
AMANN, F.W. 483–489, 571–577
AMERY, A. 377–385
AMTORP, O. 157–164
AXON, A.T.R. 115–118
AYNSLEY-GREEN, A. 349–353
BALASUBRAMANIAM, S. 435–439
BALDWIN, C.J. 579–585
BARON, P.G. 537–542, 543–548
BARRAND, M.A. 519–525, 527–535
BAUMINGER, S. 405–410
BEELEY, J.A. 179–184
BELFIELD, P.W. 139–143
BELL, M. 303–310
BERGGLUND, G. 229–232
BERNHEIM, J. 405–410
BISDEE, A. 17–23
BLOOM, S.R. 349–353
BOBIK, A. 217–219
BOONJOUR, J.P. 101–107, 171–177
BOOMSMA, F. 491–498
BRAGANZA, J.M. 303–310
BREWER, D.B. 693–702
BUHLER, F.R. 483–489, 571–577
BULLEN, A.W. 109–113
BULLOCK, S. 419–426
BUNCH, C. 191–198
BURGE, L.M. 499–506
BURKINSHAW, L. 457–461
BUTLER, J. 1–4
CALLINGHAM, B.A. 519–525, 527–535
CAMERON, I.R. 441–449
CAMERON, J.S. 81–86
CAMPBELL, D. 355–361
CAMPBELL, E.J.M. 463–466, 513–518
CANGIANO, J.L. 479–482
CARNEY, S.L. 549–554
CASTLEDEN, C.M. 587–589
CHAN, T.K. 681–688
CHAN, V. 681–688
CHETTLE, D.R. 457–461
CHOU, H.J. 633–637
CHOW, F.P.R. 327–329
CLAGUE, M.B. 233–235
CLARK, T.J.H. 11–15
CLOIDIX, J.F. 339–341
COBSELEN, I. 115–118
COFFMAN, J.D. 5–9
COHEN, R.A. 5–9
COMPSTON, J.E. 241–243
CORAZZA, G.R. 109–113
CRAYEN, A.H. 261–265
CRAWFORD, G.A. 73–80
CREMER, J.E. 87–93
CUMBERBATCH, M. 555–564
CUMMING, G. 17–23
CUMMINS, P. 33–40, 251–259
CUNNINGHAM, V.J. 87–93
DAMKJAER NIELSEN, M. 591–593
DANDONA, P. 327–329
DAVIES, I.B. 399–404
DAVIES, T.J. 595–597
DE BRUYN, J.H.B. 491–498
DERRK, F.H.M. 491–498
DICKINSON, C.J. 471–477
DIRKS, J.H. 549–554
DOBBS, R.J. 659–666
DORPMANDY, T.L. 295–301
DUNGAN, G. 145–155
DUSING, R. 467–469
ECKERISALL, P.D. 179–184
EDMONDS, C.J. 311–318
EDSTROM, S. 319–326
EISER, N.M. 363–370
EIKMAN, L. 319–326
ERIKSSON, S. 95–100
ESLER, M. 217–219
EVERY, K.L. 33–40
FAGALD, R. 377–385
FARRINGTON, K. 55–63
FINCH, A.M. 411–418
FITCH, W. 355–361
FLEHETRY, D.K. 225–228
FLECKNELL, P.A. 335–338
FLEISCH, H. 101–107, 171–177
FLEMSTRÖM, G. 427–433
FÖG-MÖLLER, F. 157–164
FRANCIS, M.J.O. 617–623
FRANKEL, H.L. 399–404
FUNK-BRENTANO, J.L. 339–341
FYHRQUIST, F. 267–272
GANDEVIA, S.C. 463–466, 513–518
GARDNER, M.L.G. 707–710
GARBER, A. 427–433
GEIJO, F. 331–334
GEORGE, C.F. 247–250
GIESE, J. 591–593
GILMORE, I.T. 65–72
GOLDSTRAW, P.W. 139–143
GRAHAM-SMITH, D.G. 191–198
GREENING, A.P. 507–512
GREGERMAN, R.I. 633–637
GUZ, A. 363–370
HAGENFELDT, L. 95–100
HALL, R. 109–113
HALL, R.J.C. 441–449
HAMILTON, G. 327–329
HAMMETT, F.G. 241–243
HANSON, P.G. 225–228
HARRIS, A.L. 191–198
HARTLING, O.J. 675–679
HARVEY, J.E. 579–585
HEATH, J.R. 667–674
HENDERSON, R.M. 543–548
HENQUET, J.W. 25–31
HENRIKSEN, O. 157–164
HERLITZ, H. 229–232
HERVEY, G.R. 457–461
HEYS, A.D. 295–301
HIGENBOTTAM, T. 11–15
HILL, G. 451–456
HILTON, P.I. 237–239
HOBBS, K.E.F. 327–329
HUGHES, J.M.B. 507–512
Author Index

HUGHES, R.L. 355–361
HUGI, K. 101–107
HUTTON, R. 327–329
ISAACSON, L.C. 283–293
ITO, G. 331–334
JACKMAN, G. 217–219
JAMES, V.H.T. 399–404
JAMES, W.P.T. 519–525, 527–535
JARRETT, R.J. 81–86
JENKINS, W. 207–212
JEWKES, R. 17–23
JOHN, M. 335–338
JOHNSON, R.H. 145–155
JONES, P.R.M. 457–461
JONES, R.B. 237–239
JONES, S.M. 703–706
JUNG, R.T. 519–525, 527–535
KARLBERG, B.E. 229–232
KARLBERG, I. 319–326
KASIDAS, G.P. 411–418
KEELING, P.W.N. 237–239
KEIR, M.J. 233–235
KELSEY, C.R. 659–666
KHO, T. 25–31
KILLIAN, K.J. 463–466, 513–518
KING, R.F.GJ. 451–456
KING, R.V. 499–506
KINOSHITA, Y. 331–334
KIOWSKI, W. 483–489, 571–577
KLASS, H.J. 303–310
KLINGMÜLLER, D. 467–469
KNIBBS, A.V. 457–461
KÖRBER, A. 467–469
KORNER, P. 217–219
KRAFT, C.A. 587–589
KRAMER, H.J. 467–469
KROOS, M.J. 185–190
LAI, C.L. 681–688
LAM, H. 157–164
LAMMIE, D.G. 145–155
LANGLEY, F. 17–23
LAWRENCE, G.M. 693–702
LECKIE, B.J. 119–130
LEONARD, P. 217–219
LEVENSON, J.A. 653–658
LILLEN, P. 377–385
LITTLER, W.A. 33–40, 251–259
LOCKHART, A. 371–375, 599–605
LOSOWSKY, M.S. 109–113
LUCAS, A. 349–353
LUNDBOM, K. 319–326
LUNDIN, S. 229–232
LUSH, D.J. 393–398
LYSBO SVENDSEN, T. 675–679
MACFIE, J. 451–456
MAGILL, P. 241–243
MAHONY, J.F. 73–80
MAKAREWICZ, W. 565–569
MANNISI, M. 435–439
MARTÍNEZ-MALDONADO, M. 479–482
MARTINEZ, P. 387–392
MATHIAS, C.J. 165–170, 399–404
MATHIE, R.T. 355–361
MATSEN III, F.A. 499–506
MATTOCK, M. 81–86
MCCORMICK, J. 625–631
MCGURK, B. 251–259
MEILTON, V. 81–86
MERTTIN, A. 267–272
MILLS, J. 363–370
MITROPULOUS, K.A. 435–439
MOHAMMED, M.N. 55–63
MONET, J.D. 339–341
MOORHEAD, J.F. 55–63
MORGAN, D.B. 457–461, 555–564
MÜHLBAUER, R.C. 171–177
MUNDAY, K.A. 393–398
MYANT, N.B. 435–439
NAIK, R.B. 165–170
NAISH, P. 47–53
NASCIMENTO, L. 479–482
NEWMAN, S.P. 55–63
NIELSEN, A.H. 41–46
NOBLE, A.R. 393–398
NOBLE, M.I.M. 17–23
OGG, C.S. 81–86
O’MALLEY, B.P. 595–597
PEARSON, S.B. 667–674
PEARL, W.S. 399–404, 639–651
PETERS, T.J. 207–212, 435–439
PLUMB, J.A. 707–710
PODJARNY, E. 405–410
POSTIGLIONE, A. 435–439
POTTER, C.G. 191–198
POULSEN, K. 41–46
POURMOTABBED, G. 633–637
QAZZAZ, S. 47–53
QUERIDO, D. 283–293
RAFFESTIN, B. 371–375
RAHN, K.H. 25–31
RASMUSSEN, S. 591–593
RATHAUS, M. 405–410
RAVID, M. 405–410
REED, B. 221–224
REE, J. 689–692
REID, J.L. 165–170
RICHARDS, H.K. 393–398
RIGDEN, B.G. 261–265
RIZZOLI, R. 101–107
ROBINSON, B.F. 659–666
ROBINSON, B.J. 109–113
RODRIGUEZ-SARGENT, C. 479–482
ROSE, G.A. 411–418
ROSENTHAL, F.D. 595–597
ROSS, B. 419–426
ROSHA, I. 327–329
ROTHWELL, J. 115–118
SAFAR, M.E. 653–658
SAGNELLA, G.A. 639–651
SALG, B. 599–605
SANCHEZ-IBARROLA, A. 47–53
SARRA, G.S. 87–93
SAVERYMUTTU, S. 659–666
SCHALEKAMP, M.A.D.H. 491–498
SCHERSTEN, T. 319–326
SCHOLS, M. 25–31
SCOTT, J. 207–212
SCOTT, J.M. 221–224
SEED, A. 17–23
SHEETY, P.S. 519–525, 527–535
SHUSTER, S. 689–692
SIGSTRÖM, L. 229–232
SILK, D.B.A. 607–615
SILVA, P. 419–426
SIMON, A.C.H. 653–658
SIMMONS, C.W. 499–506
SKAGEN, K. 157–164, 213–216
SKEEWS, H. 217–219
SMITH, G.P. 207–212
Author Index

SMITH, J.A.  543–548
SMITH, R.  617–623
SMITH, T.  311–318
SNASHALL, P.D.  363–370
STANKIEWICZ, A.  565–569
START, M.K.  81–86
STEWARD, J.H.  73–80
STOLL, R.W.  273–282
STURMIOLO, G.  303–310
SUMI, H.  199–205
SYKES, B.C.  617–623
TAKASUGI, S.  199–205
TATTERSFIELD, A.E.  579–585
TEMMAR, M.M.  653–658
THUSSEN, H.  25–31
THOM, A.  625–631
THOMAS, R.D.  139–143
THOMPSON, R.P.H.  65–72, 237–239
TIKKANEN, I.  267–272
TOKI, N.  199–205
TOMKINS, A.  131–137
TIPPING, R.M.  261–265
TÖRNRÖTH, T.  267–272
TORRETTI, J.  703–706
TOTOMOUKOU, J.M.  653–658
TRENROTH, T.  267–272
TORRETTI, J.  671–679
TUCKER, S.  87–93
TUNNEY, A.  387–392
TURNER-WARWICK, M.  261–265
TURTON, C.W.G.  261–265
ULMANN, A.  339–341
UNGAR, A.  625–631
VALETTE, H.  371–375
VAN BRUMMELEN, P.  483–489, 571–577
VAN DER HEUL, C.  185–190
VANDONGEN, R.  387–392
VAN EUK, H.G.  185–190
VAN NOORT, W.L.  185–190
VARGHESE, Z.  55–63
VARTSKY, D.  457–461
VENKATESAN, S.  435–439
VERNON, P.  17–23
WAHREN, J.  95–100
WALKER, P.  319–326
WARREN, D.J.  165–170
WASS, V.J.  81–86
WATSON, M.L.  625–631
WATT, S.J.  139–143
WEIR, D.  221–224
WEISS, E.  405–410
WEN, S.-F.  273–282
WHELPDALE, P.  625–631
WHITING, S.  261–265
WILKE, R.  467–469
WILLIAMS, K.J.  617–623
WILSON, C.A.  165–170
WONG, N.L.M.  549–554
WOOD, P.J.  579–585
WOOTTEN, R.  335–338
WORKMAN, R.J.  633–637
WRIGHT, P.D.  233–235
WYSS, C.R.  499–506
ZIMMERMAN, B.G.  343–348
Absorption, intestinal
calcium 101–107
competition 221–225
diarrhoeal disease 131–137*
dipeptides 221–225
fluid and electrolytes 131–137*
mucosal damage 115–118
oxalate 411–418
phosphate 55–63
vitamin D₃ 241–243

Absorption, renal
calcium 101–107
phosphate 171–177

Acidosis
ischaemia 537–542
metabolic 355–361
Acid protease 41–46

Acyl-CoA:cholesterol O-acyltransferase, liver
submicrosomal distribution 435–439

Adenosine ammoniagenesis in parotid gland
565–569

Adenosine 3′:5′-cyclic monophosphate, intravenous salbutamol 579–585

Adenosine 5′-phosphate, ammoniagenesis in parotid gland 565–569

Adenosine phosphate deaminase 565–569

Adenosine triphosphatase (Na⁺,K⁺-activated), erythrocyte 229–232

Adrenaline, hepatic lactate and glucose 543–548

Adrenergic facilitation, angiotensin 343–348*
Adrenergic resistance 579–585
α-Adrenoceptor, noradrenaline and vasoconstriction 483–489

β-Adrenoceptor
blockade 675–679
blockade and growth 33–40
lymphocyte cyclic AMP 587–589
renal 571–577

Adrenocorticotropic hormone, spironolactone 227–233

β-Adrenoreceptor see β-Adrenoceptor

Affinity chromatography, renin 633–637

Age
isoprenaline responses 571–577
lymphocyte cyclic AMP 587–589
noradrenaline kinetics 217–219

Airways
chronic disease 17–23
Subject Index

Baroreflexes, blood volume 193–200
Bethanidine, blood pressure and heart rate 139–143
Bicarbonate, gastric secretion 427–433
Bile acids, hepatic extraction 65–72
Bladder, urinary, sympathetic stimulation 399–404
Blood flow
borderline and essential hypertension 653–658
subcutaneous regulation 157–164, 213–216
transcutaneous oxygen tension 499–506
Blood platelets, 111In-labelled 243–248
Blood pressure
isometric exercise 139–143, 145–155
noradrenaline 483–489
saralasin 377–385
sympatholytic drugs 139–143
Blood vessels
arterial occlusion 659–666
diseases 499–506
neurogenic vasoconstriction 483–489
portacaval anastomosis 87–93
portal blood flow 355–361
pulmonary artery wedge pressure 371–375
resistance 5–9
skin 157–164, 213–216, 499–506
Blood volume, cardiovascular responses 193–200
Body composition, methandienone 457–461
Bone
hydrochlorothiazide 101–107
marrow cells 185–190, 191–198
resorption 201–210
Bone marrow cells
leukaemia 191–198
transferrin 185–190
Bradykinin 387–392
Breast cancer 201–210
Breath holding
effort sense 463–466
expiratory flow measurements 11–15
Breathing pattern
airway resistance 249–253
sustained lung inflation 667–674
Bronchitis, cardiac function 371–375
Bronchomotor tone 249–253
Caffeine, catecholamines and metabolism 527–535
Calcium
gastric secretion 427–433
plasma, hydrochlorothiazide 101–107
tubular absorption 101–107
Calcium, hydrochlorothiazide 101–107
Captopril
angiotensins 591–593
angiotensin I-converting enzyme 491–498
Captopril—continued
experimental hypertension 387–392
renin 491–498, 591–593
Carbon dioxide (14CO2), 14C-labelled substrates 233–235
Carbon monoxide diffusing capacity, intrapulmonary haemorrhage 507–512
Carcinoma, liver, antithrombin III metabolism 681–688
Cardiac muscle, see Muscle, heart
Cardiac output, chronic bronchitis 371–375
Catecholamines
borderline hypertension 25–31
caffeine 527–535
haemodialysis hypertension 165–170
isoprenaline 571–577
metabolism 183–191*
subcutaneous blood flow 157–164
Cholecystokinin, first meals 349–353*
Cholesterol, lipoprotein, home haemodialysis 81–86
Cholesterol, liver microsomal fractions 435–439
Cholesterol 7α-mono-oxygenase, liver submicrosomes 435–439
Cholic acid, hepatic extraction 65–72
Chylomicrons, plasma vitamin D 241–243
Cirrhosis
antithrombin III metabolism 681–688
primary biliary 207–212
Clonidine, blood pressure and heart rate 139–143
Coeliac disease, splenic function 109–113
Collagen chains, skin 617–623
Converting-enzyme inhibition 377–385, 387–392
Copper, liver 207–212
Corticosterone, spironolactone 227–233
Cortisol, spironolactone 227–233
Creatine kinase, primary hypothyroidism 595–597
Crystalluria, oxalate-rich foods 411–418
Cyclic AMP see Adenosine 3':5'-cyclic monophosphate
Cytosine arabinoside resistance 191–198
Dead-space measurement 17–23
Deconvolution analysis 55–63
Deoxycorticosterone acetate, salt-retention escape 467–469
Diabetes mellitus, blood volume 193–200
Dialysis, renal hypertension 625–631
Diet
fat-modified 81–86
obesity 519–525
oxalate-rich foods 411–418
Digoxin, erythrocyte sodium transport 555–564
<table>
<thead>
<tr>
<th>Subject Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>1,25-Dihydroxyvitamin D₃</td>
</tr>
<tr>
<td>Disaccharides, intestinal absorption</td>
</tr>
<tr>
<td>Doping, sports</td>
</tr>
<tr>
<td>Drug resistance</td>
</tr>
<tr>
<td>Dyspnoea, respiratory muscle fatigue</td>
</tr>
</tbody>
</table>

| Effort sense, maintained inspiration | 463–466 |
| Electrolytes, muscle, hypokalaemia | 441–449 |
| Encephalopathy | 95–100 |
| Endoplasmic reticulum, liver enzymes | 435–439 |
| Enteroglucagon, first meals | 349–353* |
| Enterotoxins | 131–137* |
| Ergometry, bicycle, hypertension | 25–31 |
| Ergotamine, small arteries | 659–666 |
| Erythrocyte adenosine triphosphatase | 229–232 |
| magnesium | 225–257 |
| pitted | 109–113 |
| sodium | 229–232, 555–564 |
| Erythroid cells | 185–190 |
| Essential hypertension | 653–658 |
| Ethane-l-hydroxy-l,l-diphosphonate, renal tubular phosphate absorption | 171–177 |

| Exercise | 543–548 |
| adrenaline | 543–548 |
| creatine kinase | 595–597 |
| forearm haemodynamics | 675–679 |
| hydrogen ion balance | 245–246 |
| immunological responses | 225–228 |
| isometric | 139–143 |
| lactate and gluconeogenesis | 537–542 |
| sensory nerves, cardiorespiratory responses | 145–155 |
| sympatholytic drugs | 139–143 |
| Expiratory flow–volume curves | 11–15 |

| Facilitation, adrenergic | 343–348* |
| Fatigue, respiratory muscle | 463–466 |
| Fat–modified diet, long-term | 81–86 |
| Fatty acids, free, caffeine | 527–535 |
| Ferritin, microheterogeneity and sialic acid | 259–262 |
| Fibrin, glomerular deposition | 47–53 |
| Fibrinolysis | 47–53 |
| 5-Fluorouracil, toxicity and pharmacokinetics | 707–710 |

| Folate | 221–224 |
| catabolism | 221–224 |
| deficiency | 131–137* |
| Forearm haemodynamics | 675–679 |
| Free fatty acids, turnover | 87–93 |
| Free radicals, scavenging enzymes | 211–219 |
| Fructose biphosphatase, muscle | 451–456 |
| Frusemide | 201–210 |
| active and inactive renin | 393–398 |
| renal papillary osmolality | 467–469 |
| renin and indomethacin | 479–482 |
| Gastric inhibitory peptide, first meals | 349–353* |
| Gastric mucosa, bicarbonate secretion | 427–433 |
| Gastrin, first meals | 349–353* |
| Gastrointestinal hormones | 349–353* |
| Geriatric patients, sodium transport | 555–564 |
| Glomerular filtration rate, haemorrhage | 703–706 |
| Glomerulus fibrin deposition | 47–53 |
| proteinuria | 693–702 |
| Gluconeogenesis hepatic, ischaemia | 537–542, 543–548 |
| renal, sodium transport | 419–426 |
| Glucose intravenous salbutamol | 579–585 |
| propranolol | 675–679 |
| turnover | 87–93 |
| Glutathione, liver | 211–219 |
| Glutathione peroxidase, iron overload | 211–219 |
| Glutathione reductase, iron overload | 211–219 |
| Glyceryl trinitrate, small arteries | 659–666 |
| Glycocoholic acid, hepatic extraction | 65–72 |
| Glycylsarcosine, intestinal absorption | 221–225 |
| Growth, adrenoceptor blockade | 33–40 |
| Gut hormones | 349–353* |
| H₁ and H₂-receptor antagonists | 363–370 |
| Haemochromatosis | 211–219 |
| Haemodialysis fat-modified diet | 81–86 |
| hypotension | 165–170 |
| Haemorrhage, renal renin | 703–706 |
| Head-up tilt, subcutaneous blood flow | 213–216 |
| Heart adrenoceptor blockade | 33–40 |
| chronic bronchitis | 371–375 |
| ferritin | 259–262 |
| sensory nerves | 145–155 |
| sympatholytic drugs | 139–143 |
| Henle’s loop, ascending, sodium rejection | 467–469 |
| Hepatic artery, blood flow | 355–361 |
| Hexokinase, muscle | 451–456 |
| Histamine receptors, asthma | 363–370 |
| Hydrallazine, small arteries | 659–666 |
| Hydrochlorothiazide calcium metabolism | 101–107 |
| renin substrate concentration | 591–593 |
| Hydrogen ion balance, exercise | 245–246 |
| β-Hydroxybuturate, plasma | 87–93 |
| 4-Hydroxy-3-methoxyxandelic acid, borderline hypertension | 25–31 |
| 3-Hydroxy-3-methylglutaryl-CoA reductase, liver microsomes | 435–439 |
| 25-Hydroxy-vitamin D plasma chylomicrons | 241–243 |
| ultraviolet irradiation | 235–242 |
| Hypercalcæmia | 201–210 |
Subject Index

Hypertension
adrenergic facilitation 343–348*
angiotensin I-converting enzyme 491–498
borderline 25–31, 653–658
essential 653–658
indomethacin 479–482
neurogenic 471–477*
noradrenaline 483–489
pulmonary 599–605*
spontaneous 229–232, 491–498
Hypertension, experimental
captopril 387–392
renal 387–392, 625–631
Hyperthyroidism, sodium transport 555–564
Hypnosis, isometric exercise pain 145–155
Hypokalaemia
cardiac and skeletal muscle 441–449
sodium transport 555–564
Hypotension, haemodialysis-induced 165–170
Hypothyroidism, primary, creatine kinase 595–597
Immunity, cellular 225–228
Indium (111In)-labelled platelets 243–248
Indomethacin, renin response 479–482
Inspiratory pressures 513–518
Interrupted electrophoresis 617–623
Intestine, small
calcium absorption 101–107
dipeptide absorption 221–225
oxalate absorption 411–418
passive permeability 115–118
peptide transport 607–615*
phosphate absorption 55–63
vitamin D3 absorption 241–243
Ion transport, kidney 419–426
Iron
overload, tissue damage 211–219
uptake 185–190
Ischaemia, lactic acidosis 537–542, 543–548
Isoleucine, blood 95–100
Isometric exercise
sensory nerves and cardiorespiratory responses 145–155
sympatholytic drugs 139–143
Isoprenaline
blood pressure 399–404
forearm blood flow 571–577
lymphocyte cyclic AMP 587–589
small arteries 659–666
Jejunum, dipeptide absorption 221–225
Kallikrein, pancreatic 199–205
Kidney
albumin excretion 693–702
blood flow, hypertension 653–658
Kidney—continued
calcium absorption 101–107
fibrin clearance 47–53
high-molecular-weight renin 639–651
hypertension 387–392
phosphate absorption 171–177
potassium transport 549–554
renin molecular weight 41–46, 119–130*, 639–651
sodium transport 419–426, 555–564
venous renin 703–706
Kidney disease
cancer 201–210
haemodialysis hypotension 165–170
hypertension 653–658
lipoprotein lipase 73–80
renal failure, erythrocyte sodium 555–564
phosphate absorption 55–63
Lactate, blood, propranolol 675–679
Lactate metabolism, ischaemia and acidosis 537–542, 543–548
Lactic acidosis 543–548
Lactulose, intestinal absorption 115–118
Leucine, blood 95–100
Leucocyte
cyclic AMP 587–589
zinc content 237–239
Leucocytosis, stress 225–228
Leukaemia, myeloblasts 191–198
Limb capacitance, morphine 5–9
Lipoprotein lipase 73–80
Liver
blood flow 355–361, 653–658
bile acid extraction 65–72
enzyme induction 221–224
free-radical scavenging enzymes 211–219
glutathione 211–219
microsomal fractions 435–439
oxygen consumption 355–361
Liver disease
bile acid extraction 65–72
carcinoma 681–688
cirrhosis 95–100, 207–212, 681–688
hypertension 653–658
organelle pathology 207–212
Lung
alveolar volume 507–512
circulation 599–605*
fluid balance 1–4*
gas mixing 17–23
haemorrhage 507–512
imaging, ventilation/perfusion 17–23
mechanics 17–23
volume 249–253, 667–674
Lymphocyte, cyclic AMP formation 587–589
L-Lysyl-L-lysine, intestinal absorption 221–225
<table>
<thead>
<tr>
<th>Subject Index</th>
<th>xi</th>
</tr>
</thead>
<tbody>
<tr>
<td>α-Macroglobulin, kallikrein interaction</td>
<td>199–205</td>
</tr>
<tr>
<td>Magnesium</td>
<td></td>
</tr>
<tr>
<td>deficiency and excess</td>
<td>549–554</td>
</tr>
<tr>
<td>menopause</td>
<td>255–257</td>
</tr>
<tr>
<td>Malate–aspartate shuttle, renal sodium transport</td>
<td>419–426</td>
</tr>
<tr>
<td>Mannitol, intestinal absorption</td>
<td>115–118</td>
</tr>
<tr>
<td>Menopause, serum, urinary, and erythrocyte magnesium</td>
<td>255–257</td>
</tr>
<tr>
<td>Metabolic rate, caffeine</td>
<td>527–535</td>
</tr>
<tr>
<td>Methandienone, athletic performance and body composition</td>
<td>457–461</td>
</tr>
<tr>
<td>Micropuncture, renal</td>
<td>171–177, 549–554</td>
</tr>
<tr>
<td>Morphine, forearm capacitance</td>
<td>5–9</td>
</tr>
<tr>
<td>Motilin, first meals</td>
<td>349–353*</td>
</tr>
<tr>
<td>Muscle, cardiac, hypokalaemia</td>
<td>441–449</td>
</tr>
<tr>
<td>Muscle, skeletal</td>
<td></td>
</tr>
<tr>
<td>blood flow in hypertension</td>
<td>653–658</td>
</tr>
<tr>
<td>fructose bisphosphatase</td>
<td>451–456</td>
</tr>
<tr>
<td>hexokinase</td>
<td>451–456</td>
</tr>
<tr>
<td>hypokalaemia</td>
<td>441–449</td>
</tr>
<tr>
<td>inspiratory</td>
<td>513–518</td>
</tr>
<tr>
<td>2-oxoglutarate dehydrogenase</td>
<td>451–456</td>
</tr>
<tr>
<td>phosphofructokinase</td>
<td>451–456</td>
</tr>
<tr>
<td>respiratory</td>
<td>463–466, 513–518</td>
</tr>
<tr>
<td>zinc content</td>
<td>237–239</td>
</tr>
<tr>
<td>Myeloblasts, leukaemia</td>
<td>191–198</td>
</tr>
<tr>
<td>Myocardial infarction, subcutaneous blood flow</td>
<td>157–164, 213–216</td>
</tr>
<tr>
<td>Neurogenic hypertension</td>
<td>471–477*</td>
</tr>
<tr>
<td>Neurotensin, first meals</td>
<td>349–353*</td>
</tr>
<tr>
<td>Noradrenaline</td>
<td></td>
</tr>
<tr>
<td>α-adrenoceptor-mediated</td>
<td></td>
</tr>
<tr>
<td>vasoconstriction</td>
<td>483–489</td>
</tr>
<tr>
<td>kinetics, age-dependence</td>
<td>217–219</td>
</tr>
<tr>
<td>tetraplegia</td>
<td>399–404</td>
</tr>
<tr>
<td>Nutrition, thyroid and catecholamines</td>
<td>183–191*</td>
</tr>
<tr>
<td>Obesity</td>
<td></td>
</tr>
<tr>
<td>caffeine</td>
<td>527–535</td>
</tr>
<tr>
<td>postprandial thermogenesis</td>
<td>519–525</td>
</tr>
<tr>
<td>Oedema, pulmonary</td>
<td>1–4*, 599–605*</td>
</tr>
<tr>
<td>Oestrogen, serum, urinary and erythrocyte magnesium</td>
<td>255–257</td>
</tr>
<tr>
<td>Oligopeptides, intestinal transport</td>
<td>607–615*</td>
</tr>
<tr>
<td>Oophorectomy, serum, urinary and erythrocyte magnesium</td>
<td>255–257</td>
</tr>
<tr>
<td>Optical isomerism, D- and L-propranolol</td>
<td>675–679</td>
</tr>
<tr>
<td>Osmolality, renal papillary</td>
<td>467–469</td>
</tr>
<tr>
<td>Osteogenesis imperfecta, skin collagen</td>
<td>617–623</td>
</tr>
<tr>
<td>Osteomalacia, ultraviolet irradiation</td>
<td>235–242</td>
</tr>
<tr>
<td>Oxalate, diet and urinary output</td>
<td>411–418</td>
</tr>
<tr>
<td>Oxidation rates, 14C-labelled substrates</td>
<td>233–235</td>
</tr>
<tr>
<td>2-Oxoglutarate dehydrogenase, muscle</td>
<td>451–456</td>
</tr>
<tr>
<td>Oxrenolol, blood pressure and heart rate</td>
<td>139–143</td>
</tr>
<tr>
<td>Oxygen</td>
<td></td>
</tr>
<tr>
<td>consumption, liver</td>
<td>355–361</td>
</tr>
<tr>
<td>skin partial pressure</td>
<td>499–506</td>
</tr>
<tr>
<td>Pain, isometric exercise</td>
<td>145–155</td>
</tr>
<tr>
<td>Pancreatic polypeptide hormone, first meals</td>
<td>349–353*</td>
</tr>
<tr>
<td>Pancreatitis, plasma kallikrein</td>
<td>199–205</td>
</tr>
<tr>
<td>Papillary sodium concentration</td>
<td>467–469</td>
</tr>
<tr>
<td>Parathyroid hormone</td>
<td></td>
</tr>
<tr>
<td>experimental undersecretion</td>
<td>101–107, 549–554</td>
</tr>
<tr>
<td>gastric bicarbonate secretion</td>
<td>427–433</td>
</tr>
<tr>
<td>Parotid gland, ammonia production</td>
<td>565–569</td>
</tr>
<tr>
<td>d-Penicillamine, primary biliary cirrhosis</td>
<td>207–212</td>
</tr>
<tr>
<td>Peptides, intestinal absorption</td>
<td>221–225, 607–615*</td>
</tr>
<tr>
<td>pH, muscle, hypokalaemia</td>
<td>441–449</td>
</tr>
<tr>
<td>Phenoxybenzamine, blood pressure and heart rate</td>
<td>139–143</td>
</tr>
<tr>
<td>Pharmacokinetics, fluorouracil</td>
<td>707–710</td>
</tr>
<tr>
<td>Phenolamine, blood pressure and heart rate</td>
<td>139–143</td>
</tr>
<tr>
<td>Phosphate absorption</td>
<td></td>
</tr>
<tr>
<td>intestinal</td>
<td>55–63</td>
</tr>
<tr>
<td>renal</td>
<td>171–177</td>
</tr>
<tr>
<td>Phosphodiesterase, caffeine</td>
<td>527–535</td>
</tr>
<tr>
<td>Phosphofructokinase, muscle</td>
<td>451–456</td>
</tr>
<tr>
<td>Plasma flow, renal renin</td>
<td>703–706</td>
</tr>
<tr>
<td>Plasma volume, chronic bronchitis</td>
<td>371–375</td>
</tr>
<tr>
<td>Plethysmography</td>
<td></td>
</tr>
<tr>
<td>forearm blood flow</td>
<td>571–577</td>
</tr>
<tr>
<td>venous occlusion</td>
<td>5–9</td>
</tr>
<tr>
<td>Portacaval anastomosis</td>
<td>87–93</td>
</tr>
<tr>
<td>Portal vein, blood flow</td>
<td>355–361</td>
</tr>
<tr>
<td>Positive end-expiratory pressure, clinical use</td>
<td>1–4*</td>
</tr>
<tr>
<td>Potassium depletion</td>
<td></td>
</tr>
<tr>
<td>cardiac and skeletal muscle</td>
<td>441–449</td>
</tr>
<tr>
<td>renal tubular transport</td>
<td>549–554</td>
</tr>
<tr>
<td>Pressure load detection, respiratory</td>
<td>513–518</td>
</tr>
<tr>
<td>Pressure–volume hysteresis, respiratory</td>
<td>249–253</td>
</tr>
<tr>
<td>Propranolol</td>
<td></td>
</tr>
<tr>
<td>growth</td>
<td>33–40</td>
</tr>
<tr>
<td>haemodynamics</td>
<td>675–679</td>
</tr>
<tr>
<td>heart</td>
<td>33–40</td>
</tr>
<tr>
<td>metabolism</td>
<td>675–679</td>
</tr>
<tr>
<td>renin substrate concentration</td>
<td>591–593</td>
</tr>
</tbody>
</table>
Subject Index

Prostaglandins
  bone resorption 201–210
  renal hypertension 625–631
  sodium balance 405–410
Prostaglandins E, F, sodium balance 405–410
Protease, human renin 625–631
Proteins, salivary and seminal 179–184
Proteinuria 693–702
Pseudorenin 633–637
Puberty, sweat gland activity 689–692
Pulmonary artery wedge pressure 371–375
Pulmonary circulation, altitude 599–605
Pulmonary oedema 1–4

Renin
  active 393–398
  assays 591–593
  borderline hypertension 25–31
  captopril 491–498, 591–593
  frusemide 393–398
  high-molecular-weight 639–651
  inactive 119–130*, 393–398
  indomethacin 479–482
  International Reference Preparation 633–637
  isoprenaline 571–577
  low-salt state 343–348*, 377–385
  molecular weight 41–46, 639–651
  renin 633–637
  renal hypertension 625–631
  spironolactone 227–233
  substrate 591–593
  tetraclegia 399–404
  volume contraction 479–482
Renin–angiotensin system
  adrenergic facilitation 343–348*
  borderline hypertension 25–31
  Renin inhibitor, renal 639–651
  Respiration, sensory nerves 145–155
  Respiratory sensations
    mouth negative pressure 513–518
    muscle fatigue 463–466
Reverse tri-iodothyronine, metabolism 183–191*
R–R interval, blood volume 193–200

Salbutamol, asthma 579–585
Saliva
  ammonia 565–569
  proteins 179–184
Salivary gland see Parotid gland
Secretin, first meals 349–353*
Semen, proteins 179–184
Sensory neuropathy, isometric exercise 145–155
Sex difference, sweat gland activity 689–692
Shock, hepatic lactate and gluconeogenesis 537–542
Sialic acid, serum ferritin homogeneity 259–262
Skeletal muscle see Muscle, skeletal
Skin
  collagen chains 617–623
  subcutaneous blood flow 157–164, 213–216
  transcutaneous oxygen tension 499–506
  ultraviolet irradiation 235–242
Sodium
  depletion 625–631
  erythrocyte transport 555–564
  hypertension 471–477*, 625–631
  papillary concentration 467–469
  prostaglandins 405–410
  renal hypertension 625–631
  renal transport 419–426
  saralasin 377–385
Spironolactone, aldosterone regulation 227–233
Spleen, coeliac disease 109–113
Starvation, plasma glucose and free fatty acids 87–93
Steroselectivity, D- and D-propranolol 675–679
Stomach
  bicarbonate secretion 427–433
  first meals 349–353*
  gastrin 349–353*
  gastric inhibitory peptide 349–353*
  Stress, immunological responses 225–228
  Subcellular fractionation, analytical 211–219
  Superoxide dismutase 211–219
  Sweat glands, puberty 689–692
  Sympathetic nervous system
    borderline hypertension 25–31
    noradrenaline 217–219, 483–489
    tetraclegia 399–404
  Sympatholytic drugs, cardiovascular response to
    exercise 139–143
Temperature, body, serum creatine kinase 595–597
Tetrahydouridine 191–198
Tetraplegia, sympathetic stimulation 399–404
Thermogenesis, obesity 519–525
Thrombocytes, In-labelled 243–248
Thromboplastin, fibrin deposition 47–53
Thyroid gland, metabolism 183–191*
Thyroparathyroidectomy, experimental 101–107, 171–177
Thyroxine, metabolism 183–191*
Timolol, growth and heart 33–40
Toxicity, 5-fluorouracil 707–710
Transaminase, renal gluconeogenesis 419–426
Transferrin, monoferric 185–190
Transplantation, renal 55–63, 73–80
**Subject Index**

---

**Transport**
- erythrocyte sodium 555–564
- intestinal peptides 607–615*
- renal potassium 549–554
- renal sodium 419–426, 555–564

**Triacylglycerols, plasma** 73–80

**Triglyceride, lipoprotein, home haemodialysis** 81–86

**Tri-iodothyronine, metabolism** 183–191*

**Tropical malabsorption** 131–137*

**Trypsin inhibitor** 639–651

**Tubule, renal**
- ascending loop 467–469
- calcium absorption 101–107
- phosphate absorption 171–177

**Ultraviolet irradiation, vitamin D** 235–242

**Uraemia, lipoprotein lipase** 73–80

**Urinary bladder, sympathetic stimulation** 399–404

**Urine**
- oxalate content 411–418
- protein content 693–702

**Valine, blood** 95–100

**Vascular diseases** 499–506

**Vascular resistance** 5–9, 659–666

**Vasoconstriction, neurogenic** 483–489

**Veins, intravenous morphine** 5–9

**Venous pressure, skin** 499–506

**Ventilation, lung, sustained inflation** 667–674

**Ventilation/perfusion lung-imaging** 17–23

**Vitamin D**
- plasma chylomicrons 241–243
- ultraviolet irradiation 235–242

**Volume–pressure hysteresis, respiratory** 249–253

**Water retention, hypertension** 471–477*

**Wedge pressure, pulmonary artery** 371–375

**Zinc, leucocytes and muscles** 237–239

---

**CORRECTIONS**

**Volume 59**

**Page 191:** to the listed addresses below the authors' names should be added Liver Unit, Kings College Hospital and Medical School, London

**Page 473, Fig. 4 legend:** for C\textsubscript{18:0}, oleic acid; C\textsubscript{18:2}, linoleic acid; C\textsubscript{18:0}, stearic acid; C\textsubscript{16:1}, myristic acid read C\textsubscript{18:1}, oleic acid; C\textsubscript{18:2}, linoleic acid; C\textsubscript{18:0}, stearic acid; C\textsubscript{16:1}, palmitoleic acid.